This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


A Roadmap to Key Pharmacologic Principles in Using Antipsychotics

Published: December 14, 2007

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
The treatment of severe mental illness has improved significantly in recent years because of advances in pharmacology and psychosocial interventions. One of the most important pharmacologic advances has been the introduction of the second generation “atypical” antipsychotics (SGAs), which are less likely to cause the neurologic movement disorders associated with older first generation antipsychotics, such as haloperidol. These neurologic side effects are usually called extrapyramidal symptoms (EPS) and include parkinsonian-type movements, rigidity, and tremor. However, with increasing new options have come new and more complex treatment decisions.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 9

Quick Links: